SciSparc Ltd. (SPRC) has released an update.
SciSparc Ltd., a clinical-stage pharmaceutical company, has announced a non-binding letter of intent to out-license its pain treatment program, SCI-160, for about $6 million, with additional payments if milestones are reached. The treatment, based on cannabinoids, has shown promise in pre-clinical studies as a potent analgesic without significant side effects, positioning the company to focus on other late-stage programs and potentially maximize shareholder value.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.
